although
advanc
immunosuppress
antimicrobi
prophylaxi
led
improv
patient
graft
surviv
respiratori
virus
continu
common
caus
morbid
mortal
immunocompromis
popul
describ
clinic
manifest
diagnosi
treatment
option
influenza
respiratori
syncyti
viru
adenoviru
infect
kidney
transplant
popul
semin
nephrol
c
elsevi
inc
right
reserv
dvanc
surgic
techniqu
immunosuppress
antimicrobi
prophylaxi
led
improv
patient
graft
surviv
among
renal
transplant
recipi
nonetheless
infect
remain
common
complic
transplant
respiratori
viral
infect
particular
common
caus
morbid
mortal
incid
season
respiratori
viral
infect
transplant
patient
reflect
one
would
expect
healthi
commun
contact
transplant
patient
influenza
human
metapneumoviru
respiratori
syncyti
viru
rsv
typic
occur
commonli
novemb
april
northern
hemispher
wherea
rhinoviru
common
fall
spring
parainfluenza
viru
piv
adenoviru
occur
throughout
entir
year
rate
infect
reflect
agematch
immunocompet
patient
nonetheless
children
becom
infect
commonli
adult
transplant
patient
sever
typic
wors
earli
posttranspl
recent
use
lymphocytedeplet
antibodi
rhinoviru
consist
commonli
identifi
respiratori
viral
infect
typic
associ
mild
selflimit
upper
respiratori
symptom
although
seriou
complic
occur
rhinoviru
coronaviru
piv
rsv
influenza
preval
clinic
present
respiratori
viral
infect
reflect
typic
symptom
experienc
nonimmunocompromis
patient
although
atyp
asymptomat
present
particularli
rhinoviru
seen
commonli
transplant
recipi
otherwis
healthi
individu
respiratori
virus
detect
five
time
frequent
recipi
respiratori
symptom
rate
progress
lower
tract
diseas
greater
certain
virus
ie
influenza
rsv
piv
pediatr
age
group
earli
onset
transplant
greater
net
state
immun
suppress
highest
rate
lymphodeplet
outcom
infect
associ
strongli
site
involv
net
state
immun
suppress
avail
use
antivir
agent
patient
heavili
immun
suppress
lower
tract
involv
fail
receiv
time
antivir
therapi
like
experi
complic
cours
die
review
outlin
optim
diagnost
strategi
detect
respiratori
virus
epidemiolog
key
respiratori
viral
infect
renal
transplant
patient
well
avail
prevent
therapeut
strategi
specif
sign
symptom
uniqu
one
viru
gener
respiratori
viral
infect
trigger
releas
local
system
cytokin
gener
respons
sign
symptom
respiratori
viral
infect
patient
may
experi
given
similar
cytokin
releas
respons
variou
respiratori
virus
clinic
pictur
often
clinic
challeng
discrimin
result
specif
diagnosi
infect
viru
requir
laboratori
techniqu
gener
diagnosi
made
detect
serolog
respons
viral
infect
detect
viral
encod
protein
antigen
detect
detect
viral
rnadna
cell
cultur
serolog
typic
limit
studi
requir
collect
acut
time
ill
convalesc
week
recoveri
antibodi
titer
limit
benefit
acut
diagnosi
transplant
patient
may
fail
mount
normal
antibodi
respons
histor
viral
cultur
consid
gold
standard
advent
molecular
diagnost
shown
viral
cultur
variabl
sensit
certain
virus
may
miss
infect
cultur
labori
take
day
becom
posit
rapid
shell
vial
cultur
techniqu
provid
rapid
result
enhanc
sensit
concentr
viru
use
antigen
detect
viral
antigen
detect
fluoresc
antibodi
appli
primari
clinic
specimen
cultur
colorimetr
detect
specif
viral
protein
gener
advantag
provid
rel
rapid
result
may
limit
sensit
particularli
case
rapid
antigen
detect
method
adult
transplant
recipi
molecular
diagnost
ie
polymeras
chain
reaction
pcr
becom
wide
avail
advantag
allow
multiplex
therebi
detect
multipl
virus
one
test
addit
assay
gener
highest
sensit
avail
diagnost
test
import
rememb
howev
despit
excel
sensit
poorli
collect
sampl
may
yield
falseneg
result
patient
lower
respiratori
tract
infect
may
neg
test
upper
respiratori
tract
specimen
final
diagnost
sensit
individu
virus
vari
specif
assay
use
well
result
dilig
collect
specimen
knowledg
limit
assay
use
laboratori
essenti
interpret
result
influenza
rsv
larg
number
rapid
antigen
assay
avail
rapid
detect
specif
viru
although
posit
result
gener
repres
true
infect
assay
poor
sensit
particularli
immunocompromis
adult
patient
multiplex
reversetranscriptas
pcr
rtpcr
test
prefer
way
diagnos
influenza
parainfluenza
transplant
set
even
though
requir
time
expertis
special
equip
although
sensit
specif
variat
genom
viru
infect
individu
patient
yield
falseneg
result
rtpcr
test
respiratori
virus
pcr
prefer
diagnost
strategi
low
yield
cultur
limit
fluoresc
antibodi
avail
adenoviru
uniqu
although
pcr
prefer
diagnost
test
neg
test
upper
lower
airway
may
exclud
infect
assay
detect
serotyp
furthermor
adenoviru
replic
occur
absenc
clinic
symptom
posit
test
must
contextu
patient
present
sign
symptom
adenoviru
caus
rang
clinic
diseas
respiratori
involv
may
occur
late
result
detect
compart
includ
blood
urin
cerebrospin
fluid
consid
depend
clinic
present
patient
final
unlik
pcr
assay
virus
clear
methodolog
quantit
viral
load
test
adenoviru
quantit
viral
load
test
allow
care
monitor
trend
determin
need
antivir
case
persist
increas
viral
load
respons
antivir
therapi
final
adenoviru
diagnost
typic
requir
biopsi
involv
tissu
assess
histopatholog
chang
compat
adenoviru
infect
patholog
help
distinguish
local
infect
ie
adenoviru
interstiti
nephriti
organ
reject
patholog
influenza
orthomyxoviru
type
b
c
influenza
virus
negativesens
singlestrand
segment
rna
virus
classifi
subtyp
basi
surfac
hemagglutinin
ha
neuraminidas
na
antigen
drift
occur
small
chang
individu
amino
acid
ha
na
develop
time
allow
viru
evad
exist
humor
immun
antigen
drift
account
need
updat
compon
virus
influenza
vaccin
time
altern
antigen
shift
occur
entir
novel
ha
na
circul
popul
often
result
pandem
world
recent
experienc
emerg
novel
viru
epidemiolog
gener
studi
influenza
solidorgan
transplant
recipi
focus
lung
transplant
recipi
result
epidemiolog
signific
influenza
nonlung
solidorgan
transplant
recipi
less
well
understood
nonetheless
induct
mainten
immun
suppress
use
similar
directli
impact
number
function
lymphocyt
lymphocyt
critic
control
clearanc
influenza
organ
transplant
recipi
increas
risk
influenza
infect
complic
season
influenza
typic
associ
selflimit
infect
typic
upper
airway
immunocompromis
patient
influenza
sever
diseasecompl
longer
viral
shed
antivir
resist
although
show
fewer
clinic
symptom
sign
clinic
assess
influenza
may
affect
transplant
patient
winter
month
typic
howev
somewher
patient
infect
annual
sever
infect
includ
pneumonia
increas
risk
bacteri
fungal
superinfect
describ
recipi
solidorgan
transplant
recipi
clinic
manifest
influenza
best
data
influenza
transplant
patient
come
larg
studi
collect
data
retrospect
case
novel
influenza
among
us
canadian
transplant
recipi
kidney
liver
heart
lung
transplant
recipi
median
time
sinc
transplant
year
cough
adult
pediatr
fever
adult
pediatr
common
symptom
although
less
common
immunocompet
patient
likewis
symptom
commonli
associ
influenza
myalgia
adult
pediatr
sore
throat
adult
pediatr
occur
infrequ
transplant
popul
sixtyon
percent
lymphopen
time
present
requir
hospit
twentyf
percent
develop
pneumonia
typic
viral
pneumonia
admit
intens
care
unit
prevent
influenza
prevent
use
vaccin
antivir
medic
influenza
vaccin
current
recommend
transplant
patient
close
contact
advisori
committe
immun
practic
american
societi
transplant
infecti
diseas
commun
practic
intern
societi
heart
lung
transplant
risk
replic
diseas
use
live
attenu
inhal
vaccin
contraind
transplant
recipi
discourag
close
contact
limit
suppli
vaccin
live
attenu
vaccin
avail
use
close
contact
consid
strict
attent
good
hand
hygien
practic
minim
contact
secret
eg
share
food
drink
direct
saliva
contact
unfortun
rate
influenza
vaccin
among
transplant
recipi
close
contact
remain
low
part
outdat
concern
clinician
safeti
efficaci
inactiv
inject
vaccin
date
studi
season
pandem
vaccin
transplant
patient
recent
review
detail
although
rel
vaccin
efficaci
variabl
safeti
intervent
without
doubt
associ
increas
risk
allograft
reject
influenza
vaccinationa
patient
encourag
receiv
vaccin
annual
need
special
monitor
posttranspl
influenza
vaccin
typic
slightli
reduc
efficaci
compar
healthi
control
whether
measur
antibodi
tcell
respons
mitogen
although
evid
even
limit
among
transplant
recipi
inject
vaccin
effect
prevent
laboratoryconfirm
influenza
even
patient
limit
serolog
respons
vaccin
efficaci
vaccin
like
depend
lymphopenia
net
state
immun
suppress
individu
patient
patient
enhanc
immun
suppress
vaccin
earli
posttranspl
recent
receiv
lymphocytedeplet
agent
andor
rituximab
may
reduc
respons
vaccin
altern
prevent
strategi
consid
slightli
decreas
respons
vaccin
close
contact
transplant
patient
includ
associ
health
care
worker
vaccin
may
reduc
risk
diseas
exposur
protect
around
patient
patient
contraind
vaccin
individu
would
predict
poor
respons
vaccin
enhanc
immun
suppress
recent
lymphodeplet
use
rituximab
use
antivir
prophylaxi
could
help
protect
individu
influenza
widespread
resist
inhibitor
current
neuraminidas
inhibitor
recommend
prophylaxi
oseltamivir
effect
prophylaxi
gener
well
toler
immunocompet
immunocompromis
patient
group
recent
prospect
studi
season
oseltamivir
mg
day
versu
placebo
document
mark
reduct
rtpcrproven
influenza
infect
versu
infect
individu
receiv
prophylaxi
period
peak
influenza
circul
commun
sever
immunocompet
patient
develop
oseltamivir
resist
place
oseltamivir
mg
day
prophylaxi
exposur
index
case
typic
antivir
start
hour
exposur
ongo
asymptomat
replic
possibl
postexposur
prophylaxi
consid
immunocompromis
patient
mani
would
recommend
use
full
treatment
dose
twice
daili
day
exposur
prevent
clinic
signific
infect
emerg
antivir
resist
strict
attent
infect
control
practic
use
set
transplant
patient
receiv
care
import
nosocomi
transmiss
influenza
respiratori
virus
well
document
transplant
set
transmiss
occur
infect
patient
visitor
clinic
staff
current
center
diseas
control
guidelin
updat
constantli
review
annual
outbreak
new
viru
final
influenza
document
transmit
organ
donor
recipi
typic
lung
transplant
import
recogn
individu
sever
ill
influenza
may
becom
transient
virem
particularli
infect
new
animalderiv
strain
influenza
donor
document
influenza
replic
use
lung
donor
patient
risk
viremia
use
donor
donorderiv
influenza
transmiss
like
result
atyp
clinic
present
test
nontyp
specimen
stool
urin
blood
consid
donorderiv
diseas
consid
report
local
organ
procur
organ
immedi
alert
clinician
care
recipi
organ
use
donor
confirm
infect
influenza
use
system
activ
antivir
full
treatment
dose
day
posttranspl
consid
treatment
two
class
antivir
current
avail
treat
influenza
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
laninamivir
japan
peramivir
china
japan
south
korea
unit
state
widespread
resist
among
circul
strain
influenza
current
preclud
use
inhibitor
resist
time
neuraminidas
inhibitor
activ
influenza
b
virus
rare
resist
may
emerg
limit
efficaci
individu
neuraminidas
inhibitor
typic
cours
treatment
influenza
set
prolong
shed
resist
neuraminidas
inhibitor
occur
secondari
mutat
neuraminidas
hemagglutinin
gene
specif
mutat
determin
antivir
specif
viru
resist
degre
crossresist
recent
strain
resist
secondari
mutat
na
gene
associ
signific
increas
inhibitori
concentr
oseltamivir
lesser
extent
peramivir
differ
mutat
may
occur
especi
antivir
oseltamivir
use
patient
resist
consid
patient
develop
influenza
recent
exposur
antivir
agent
use
either
treatment
prophylaxi
failur
improv
clinic
despit
day
antivir
therapi
addit
patient
prolong
shed
test
serial
detect
emerg
resist
test
resist
either
phenotyp
assay
assay
genotyp
detect
wide
rang
mutat
ie
mutat
use
soon
resist
consid
switch
agent
predict
activ
typic
zanamivir
consid
prospect
studi
optim
time
dose
durat
antivir
lung
transplant
recipi
number
studi
review
outcom
antivir
therapi
retrospect
involv
lung
transplant
recipi
gener
none
studi
includ
serial
quantit
assess
viral
replic
studi
robust
serial
qualit
assess
viral
replic
gener
antivir
therapi
appear
decreas
mortal
reduc
risk
develop
viral
pneumonia
start
earli
delay
initi
therapi
associ
higher
frequenc
progress
pneumonia
death
studi
appear
benefit
patient
even
symptom
ongo
longer
hour
result
transplant
patient
suspect
influenza
initi
antivir
therapi
irrespect
durat
symptom
therapi
await
diagnost
studi
furthermor
patient
lower
tract
involv
may
neg
nasal
swab
test
even
pcr
therapi
continu
influenza
rule
upper
lower
airway
gener
oseltamivir
well
toler
shed
may
prolong
result
longer
cours
usual
cours
like
requir
transplant
recipi
expert
recommend
treat
erad
replic
confirm
studi
investig
safeti
efficaci
inhal
zanamivir
intraven
peramivir
transplant
patient
nonetheless
consid
altern
therapi
oseltamivir
intraven
therapi
believ
need
intraven
peramivir
given
mgd
renal
adjust
dose
day
singledos
intraven
peramivir
appropri
transplant
patient
virolog
rsv
envelop
singlestrand
negativesens
rna
viru
initi
isol
chimpanze
later
human
infant
member
paramyxovirida
famili
human
be
chimpanze
host
rsv
two
antigen
type
b
may
cocircul
virus
one
subtyp
predomin
strain
nucleotid
ident
rsv
lack
hemagglutinin
neuraminidas
activ
surfac
transmembran
surfac
glycoprotein
spike
fig
genom
contain
gene
encod
protein
one
gene
encod
two
overlap
read
frame
second
gene
second
start
codon
protein
gs
protein
encod
includ
transcript
process
factor
transcript
regulatori
protein
matrix
protein
protein
along
associ
rnacontain
nucleocapsid
complex
protein
nucleoprotein
phosphoprotein
polymeras
protein
also
three
transmembran
surfac
protein
fusion
attach
glycoprotein
propos
small
hyodrophob
viroporin
protein
gs
truncat
form
g
secret
epidemiolog
rsv
ubiquit
viru
infect
upper
lower
respiratori
tract
rsv
infect
age
infant
young
children
affect
suspect
year
age
children
experienc
least
one
rsv
infect
unit
state
major
rsv
season
typic
run
novemb
late
march
earli
april
although
children
infect
often
compar
adult
rsv
infect
caus
sever
ill
high
rate
morbid
mortal
elderli
immunocompromis
particular
patient
lymphopenia
immunocompromis
popul
includ
stem
cell
transplant
solidorgan
transplant
sot
patient
rsv
infect
may
progress
sever
lifethreaten
lower
respiratori
tract
infect
one
center
sot
infect
account
approxim
half
immunocompromis
popul
infect
depend
transplant
organ
wide
rang
mortal
rate
patient
solidorgan
transplant
major
publish
literatur
regard
rsv
infect
sot
lung
transplant
patient
howev
increas
data
renal
transplant
patient
even
without
specif
therapi
mortal
rsv
infect
adult
renal
transplant
patient
low
clinic
manifest
rsv
symptom
infect
rsv
similar
respiratori
virus
symptom
often
may
includ
fever
cough
nasal
sinu
congest
pain
labor
breath
headach
even
wheez
lower
respiratori
tract
infect
present
fever
present
cough
present
approxim
rhinorrhea
present
patient
imag
radiograph
comput
tomographi
ct
yield
varieti
find
case
seri
solidorgan
transplant
rsv
infect
includ
kidney
describ
roentgenogram
normal
find
unilater
focal
consolid
diffus
interstiti
opac
groundglass
opac
lung
nodul
diffus
diseas
consolid
may
present
ct
pleural
effus
small
cavit
also
may
observ
howev
ct
abnorm
may
observ
patient
durat
viral
shed
healthi
adult
approxim
day
howev
sot
stem
cell
transplant
popul
averag
approxim
day
day
treatment
rsv
infect
optim
treatment
rsv
infect
renal
transplant
popul
well
defin
support
therapi
remain
mainstay
therapi
stem
cell
transplant
popul
use
therapi
ribavirin
remain
controversi
howev
data
suggest
treatment
aerosol
ribavirin
without
immunomodul
intraven
immunoglobulin
ivig
provid
benefit
especi
treat
upper
respiratori
tract
diseas
prevent
progress
lower
respiratori
tract
diseas
also
data
support
oral
ribavirin
use
stem
cell
transplant
popul
solidorgan
transplant
popul
treatment
antivir
agent
immunomodul
remain
undefin
much
data
regard
sot
rsv
therapi
lung
transplant
patient
pauciti
data
renal
transplant
patient
subgroup
six
renal
transplant
patient
one
liverkidney
one
pancreaskidney
three
six
patient
treat
use
either
inhal
two
three
oral
one
three
ribavirin
liverkidney
patient
receiv
antivir
therapi
one
patient
receiv
inhal
ribavirin
ivig
kidneypancrea
patient
receiv
inhal
ribavirin
palivizumab
human
monoclon
antibodi
rsv
one
kidney
transplant
patient
receiv
inhal
ribavirin
ivig
palivizumab
none
six
patient
die
five
patient
prednison
tacrolimu
mycophenol
mofetil
one
patient
mycophenol
mofetil
sirolimu
durat
ribavirin
inhal
andor
oral
gener
day
data
remain
inconclus
outcom
mortal
benefit
palivizumab
treatment
rsv
stem
cell
sot
popul
durat
ivig
therapi
mgkg
everi
hour
gener
rang
day
tabl
show
common
treatment
consider
patient
moder
sever
infect
caus
rsv
adenoviru
adv
origin
isol
human
adenoid
sampl
soon
recov
patient
respiratori
diseas
differ
type
identifi
caus
sever
type
clinic
syndrom
includ
upper
lower
respiratori
tract
infect
fulmin
hepat
epidem
keratoconjunct
well
dissemin
diseas
transplant
kidney
infect
kidney
transplant
recipi
contrast
viral
infect
rsv
influenza
season
predilect
adenovir
infect
virolog
adenoviru
nonenvelop
doublestrand
dna
viru
famili
adenovirida
character
icosahedr
capsid
compos
three
major
protein
call
hexon
penton
fiber
total
capsomer
subunit
form
surfac
vertic
penton
fiber
protein
locat
fiber
protein
import
interact
cellular
receptor
fig
seven
subgroup
term
g
serotyp
differ
genotyp
identifi
within
serotyp
adenoviru
ubiquit
subtyp
b
c
e
adenoviru
known
circul
global
implic
outbreak
tissu
tropism
account
certain
subgroup
serotyp
correl
differ
diseas
manifest
tabl
exampl
dissemin
diseas
associ
subgroup
c
f
although
subtyp
associ
part
epidem
keratoconjunct
shown
caus
dissemin
diseas
renal
transplant
patient
hemorrhag
cystiti
associ
subgroup
serotyp
respiratori
tract
diseas
associ
subgroup
c
e
serotyp
gastrointestin
diseas
associ
subgroup
f
serotyp
g
inhal
hour
everi
hour
g
hour
daili
day
oral
ribavirin
mg
oral
twice
daili
day
addit
one
earlierdescrib
option
also
may
use
ivig
mgkg
intraven
everi
day
day
age
year
individu
serolog
evid
past
exposur
year
age
individu
evid
exposur
exposur
may
occur
differ
mean
adv
may
caus
sever
diseas
manifest
transmiss
occur
fomit
aerosol
droplet
fecalor
spread
infect
tissu
blood
addit
latent
infect
occur
adv
shown
resid
lymphoid
tissu
renal
parenchyma
may
reactiv
immunocompromis
patient
adv
infect
detect
occur
time
posttranspl
period
even
littl
week
posttranspl
sot
recipi
asymptomat
carriag
shed
adv
note
occur
week
month
gastrointestin
diseas
prolong
period
adv
viruria
even
year
asymptomat
detect
adv
dnaemia
renal
transplant
patient
kidney
transplant
recipi
risk
factor
adv
infect
includ
pediatr
age
use
antilymphocyt
antibodi
donorpositiverecipientneg
adv
serostatu
asymptomat
viremia
common
sot
recipi
one
studi
show
rate
renal
transplant
patient
viremia
alon
associ
risk
progress
diseas
routin
screen
adv
dnaemia
recommend
adenoviru
may
detect
asymptomat
shed
stool
urin
presenc
clinic
diseas
therefor
import
distinguish
true
diseas
asymptomat
shed
immunocompromis
popul
particularli
sot
patient
adv
typic
involv
transplant
organ
although
infect
tend
less
common
seriou
renal
transplant
patient
mortal
rate
report
renal
transplant
patient
patient
shown
develop
sever
adv
clinic
diseas
common
present
diseas
renal
allograft
patient
includ
hemorrhag
cystiti
interstiti
nephriti
symptom
hemorrhag
cystiti
typic
includ
fever
hematuria
without
dysuria
suprapub
pain
interstiti
nephriti
allograft
biopsi
find
variabl
includ
interstiti
infiltr
lymphocyt
monocyt
plasma
cell
neutrophil
viral
inclus
may
observ
granuloma
may
present
well
granulomat
chang
viral
cytopath
effect
serv
import
clue
differenti
adv
infect
acut
reject
tubular
cell
necrosi
viral
cytopath
effect
although
glomeruli
appear
free
inflamm
blood
vessel
part
free
inflamm
rare
find
fibrin
accumul
arteri
wall
number
parenthes
repres
predomin
serotyp
associ
describ
mani
infect
selflimit
howev
necrot
tubulointerstiti
nephriti
allograft
dysfunct
lead
dialysi
obstruct
uropathi
occur
adenoviru
upper
respiratori
tract
diseas
pneumon
gastrointestin
diseas
dissemin
diseas
two
organ
effect
describ
renal
transplant
recipi
well
treatment
asymptomat
viremia
may
occur
frequent
adv
infect
renal
transplant
patient
minor
selflimit
mainstay
treatment
remain
reduct
immunosuppress
although
optim
chang
immunosuppress
regimen
known
remain
standard
consensu
optim
antivir
medic
regimen
guanosid
analog
ribavirin
shown
efficaci
adv
infect
recommend
vitro
activ
ganciclovir
adv
report
case
report
treat
adv
infect
although
prospect
random
clinic
trial
data
support
use
nucleosid
analog
cytidin
monophosph
cidofovir
adv
infect
becom
standard
care
medic
center
cidofovir
act
promot
viral
dna
chain
termin
taken
substrat
viral
dna
polymeras
immunocompromis
popul
cidofovir
note
decreas
viral
load
decreas
viral
load
turn
also
correl
clinic
improv
signific
risk
nephrotox
use
cidofovir
signific
side
effect
monitor
use
cidofovir
includ
neutropenia
decreas
intraocular
pressur
anterior
uveiti
metabol
acidosi
current
two
main
dose
regimen
support
literatur
first
three
time
weekli
regimen
dose
mgkg
intraven
second
mgkg
intraven
weekli
initi
dose
continu
minimum
week
follow
cidofovir
mgkg
intraven
everi
week
monitor
resolut
symptom
three
neg
adv
pcr
origin
affect
site
dose
adjust
must
made
renal
function
hemodialysi
avoid
hour
hour
dose
allow
intracellular
distribut
cidofovir
lipidlink
deriv
cidofovir
brincidofovir
formerli
chimerix
durham
nc
shown
promis
vitro
vivo
activ
adv
brincidofovir
lipid
moieti
allow
administ
oral
rather
intraven
allow
enter
cell
readili
lipid
moieti
cleav
allow
leav
cell
easili
importantli
surprisingli
given
parent
compound
brincidofovir
nonnephrotox
use
ivig
lymphocyt
infus
remain
controversi
appear
clear
benefit
time
